Metabolic · FDA Approved
Liraglutide (Saxenda/Victoza)
FDA-approved
01 · Overview
A GLP-1 receptor agonist with 97% homology to native GLP-1, modified with a 16-carbon fatty acid chain that binds albumin and protects against DPP-4 degradation, giving an elimination half-life of about 13 hours that allows once-daily dosing (PMID 21923591). Liraglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety.
It was approved for chronic weight management (Saxenda) in 2014, and generic versions have since been approved.
02 · Research summary & key findings
In SCALE Obesity and Prediabetes, adults without diabetes lost a mean 8.4 kg at 56 weeks versus 2.8 kg with placebo, and 63% lost at least 5% of body weight (PMID 26132939). The LEADER trial showed a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes patients at high cardiovascular risk (hazard ratio 0.87) (PMID 27295427). FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014).
03 · Regulatory status
Liraglutide (Saxenda/Victoza) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Liraglutide (Saxenda/Victoza) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Liraglutide (Saxenda/Victoza) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (daily)
References
- [1]Liraglutide: clinical pharmacology and considerations for therapy Pharmacotherapy, 2011. PMID 21923591
- [2]A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med, 2015. PMID 26132939
- [3]Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med, 2016. PMID 27295427
Primary literature
- PubMed: "Liraglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Liraglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Liraglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.